Dexamethasone-sparing Strategies in Anthracycline and Cyclophosphamide-based Chemotherapy with a Focus on 5-HT3 Receptor Antagonists: a Network Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Aug 12

PMID 39132500

Authors

Daichi Watanabe

Hirotoshi Iihara

Ryo Kobayashi

Hironori Fujii

Ryutaro Mori

Keisuke Kumada

Masahito Shimizu

Manabu Futamura

Akio Suzuki

Affiliations

Soon will be listed here.

Abstract

Background: The effectiveness of a dexamethasone-sparing strategy in the treatment of breast cancer with anthracycline-cyclophosphamide therapy when combined with first-generation 5-HT3 receptor antagonists (RAs) and neurokinin-1 RAs is unclear. This is attributable to a lack of evidence from direct comparison of multiple doses of DEX to a single dose of DEX in combination with first-generation 5-HT3 RAs in anthracycline-cyclophosphamide therapy. Our goal was to clarify the impact of dexamethasone-sparing strategies that involve both first-generation 5-HT3 RAs and palonosetron when combined with neurokinin-1 RAs, using a network meta-analysis.

Materials And Methods: A literature search was conducted on PubMed/Medline for articles published up to July 4, 2023. We included randomized controlled trials which assessed the efficacy of antiemetic regimens which combined 5-HT3 RAs and dexamethasone, with or without neurokinin-1 RAs, for the initial dose in anthracycline-cyclophosphamide therapy for patients with breast cancer. The primary outcome was the proportion of patients achieving a complete response during the delayed phase (CR-DP).

Results: The difference in the proportion of patients achieving CR-DP between multiple and single doses of dexamethasone was 0.1% (95%CI: -12.4 to 12.5) with palonosetron and neurokinin-1 RAs, compared to 5.3% (95%CI: -13.4 to 23.0) with a single dose of a first-generation 5-HT3 receptor antagonist. Additionally, the difference was 12.7% (95% CI: -2.8 to 28.2) when comparing palonosetron against first-generation 5-HT3 RAs in combination with a single dose of dexamethasone and neurokinin-1 RAs.

Conclusion: Palonosetron is recommended rather than a single dose of first-generation 5-HT3 RAs in dexamethasone-sparing strategies for anthracycline-cyclophosphamide therapy.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Zhang Y, Yang Y, Zhang Z, Fang W, Kang S, Luo Y . Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. J Natl Cancer Inst. 2016; 109(2). DOI: 10.1093/jnci/djw217. View

Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S . One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist. 2019; 24(12):1593-1600. PMC: 6975929. DOI: 10.1634/theoncologist.2019-0133. View

Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K . A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer. 2022; 128(8):1692-1698. PMC: 9306508. DOI: 10.1002/cncr.34088. View

Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H . Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer. 2015; 24(3):1405-11. PMC: 4729792. DOI: 10.1007/s00520-015-2905-4. View

Navari R, Binder G, Molasiotis A, Herrstedt J, Roeland E, Ruddy K . Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. Oncologist. 2022; 28(3):208-213. PMC: 10020801. DOI: 10.1093/oncolo/oyac240. View

Ho K, Marshall R, Walters S . Use of odds ratios on anaesthesia related studies. Anaesth Intensive Care. 2003; 31(4):392-5. DOI: 10.1177/0310057X0303100407. View

Bajpai J, Kapu V, Rath S, Kumar S, Sekar A, Patil P . Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised,.... Lancet Oncol. 2024; 25(2):246-254. DOI: 10.1016/S1470-2045(23)00628-9. View

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni M, Bondarenko I . A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014; 25(7):1328-1333. PMC: 4071754. DOI: 10.1093/annonc/mdu101. View

10.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A . Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98(11):2473-82. DOI: 10.1002/cncr.11817. View

11.

Wenzell C, Berger M, Blazer M, Crawford B, Griffith N, Wesolowski R . Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Support Care Cancer. 2013; 21(10):2845-51. PMC: 3769492. DOI: 10.1007/s00520-013-1865-9. View

12.

Zhang J, Carlin B, Neaton J, Soon G, Nie L, Kane R . Network meta-analysis of randomized clinical trials: reporting the proper summaries. Clin Trials. 2013; 11(2):246-62. PMC: 3972291. DOI: 10.1177/1740774513498322. View

13.

Hamza T, van Houwelingen H, Stijnen T . The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol. 2007; 61(1):41-51. DOI: 10.1016/j.jclinepi.2007.03.016. View

14.

Zelek L, Debourdeau P, Bourgeois H, Wagner J, Brocard F, Lefeuvre-Plesse C . A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. Oncologist. 2021; 26(10):e1870-e1879. PMC: 8488783. DOI: 10.1002/onco.13888. View

15.

Gallis J, Turner E . The risks of odds ratios: Relative risks are more naturally understood. BJOG. 2019; 126(13):1556-1557. DOI: 10.1111/1471-0528.15507. View

16.

Rojas C, Thomas A, Alt J, Stathis M, Zhang J, Rubenstein E . Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2009; 626(2-3):193-9. DOI: 10.1016/j.ejphar.2009.10.002. View

17.

Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K . Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020; 25(3):e589-e597. PMC: 7066686. DOI: 10.1634/theoncologist.2019-0527. View

18.

Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C . Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic.... Ann Oncol. 2010; 21(5):1083-8. DOI: 10.1093/annonc/mdp584. View

19.

Rapoport B, Jordan K, Boice J, Taylor A, Brown C, Hardwick J . Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2009; 18(4):423-31. DOI: 10.1007/s00520-009-0680-9. View

20.

Schwartzberg L, Modiano M, Rapoport B, Chasen M, Gridelli C, Urban L . Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised,.... Lancet Oncol. 2015; 16(9):1071-1078. DOI: 10.1016/S1470-2045(15)00034-0. View